Advances in Experimental Radiotherapy

Dear Colleagues,

Radiotherapy remains one of the most common and rapidly evolving treatments for cancer. However, currently, radiotherapy is rarely given as a single treatment but increasingly in combination with biologicals and taking into account biological mechanisms. More accurate therapies such as proton and carbon therapy have opened novel avenues for alternative dose planning/distribution, but biological and mechanistic differences in the cellular response between photon and particle treatment need further elucidation. Combination therapies involving hyperthermia, immune checkpoint inhibitors DDR inhibitors, and (stem cell) metabolism interference are currently finding their way to the clinic. In addition to these, modulation and prediction of response to radiation involving cancer therapies will optimize current empirical data-driven models based on dose distribution and clinical outcome. (Cancer) stem cell response, circulating biomarkers, and the microbiome have large implications on the prediction and adaptation of the radiation response.

This Special Issue of Cancers on “Advances in Experimental Radiotherapy” features the current standing of the field of radiotherapy and the application and potential emerging biological approaches to improve treatment outcome in radiotherapy. For ultimate clinical application of combination treatments, we must better understand the biology of the radiation response and ways to predict and develop novel ways to modulate both tumor and normal tissue responses. Those factors will ultimately increase tumor control and quality of life of the patients.

Prof. Dr. Rob P. Coppes
Prof. Dr. Marc A.G.G. Vooijs
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.